Cardiol Therapeutics (TSX:CRDL) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

CRDL Overzicht aandelen

Cardiol Therapeutics Inc., een life sciences bedrijf in een klinische fase, richt zich op het onderzoek naar en de ontwikkeling van anti-fibrotische en anti-inflammatoire therapieën voor de behandeling van hartaandoeningen.

Over het bedrijf

CRDL fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Verhandeld tegen 97.5% onder onze schatting van de reële waarde

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( CA$0 )

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Aandeelhouders zijn het afgelopen jaar verwaterd

Cardiol Therapeutics Inc. Concurrenten

Small Pharma

TSXV:DMT

CA$50.4m

NervGen Pharma

TSXV:NGEN

CA$170.5m

Planet 13 Holdings

CNSX:PLTH

CA$263.4m

Organigram Holdings

TSX:OGI

CA$254.1m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Cardiol Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	CA$2.69
52 Week Hoogtepunt	CA$4.26
52 Week Laag	CA$0.91
Bèta	0.70
11 maand verandering	8.03%
3 maanden verandering	-2.18%
1 Jaar Verandering	124.17%
33 jaar verandering	-37.73%
5 jaar verandering	-7.88%
Verandering sinds IPO	-35.18%

Recent nieuws en updates

We're Not Very Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate

Sep 12

Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Deliver On Growth Plans?

May 01

Recent updates

We're Not Very Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate

Sep 12

Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Deliver On Growth Plans?

May 01

Will Cardiol Therapeutics (TSE:CRDL) Spend Its Cash Wisely?

Jan 06

Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Invest In Growth?

Sep 13

We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

May 24

Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Dec 09

We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

Aug 19

Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Apr 18

Companies Like Cardiol Therapeutics (TSE:CRDL) Are In A Position To Invest In Growth

Jan 03

Rendement voor aandeelhouders

	CRDL	CA Pharmaceuticals	CA Markt
7D	0%	0.6%	-0.3%
1Y	124.2%	-3.8%	21.1%

Rendement versus industrie: CRDL overtrof de Canadian Pharmaceuticals industrie, die het afgelopen jaar een rendement -6.7 % opleverde.

Rendement versus markt: CRDL overtrof de Canadian markt, die het afgelopen jaar een rendement opleverde van 24.6 %.

Prijsvolatiliteit

Is CRDL's price volatile compared to industry and market?
CRDL volatility
CRDL Average Weekly Movement	9.2%
Pharmaceuticals Industry Average Movement	10.1%
Market Average Movement	8.2%
10% most volatile stocks in CA Market	17.0%
10% least volatile stocks in CA Market	3.1%

Stabiele aandelenkoers: CRDL heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 9% ) van CRDL is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2017	n/a	David Elsley	www.cardiolrx.com

Cardiol Therapeutics Inc., een life sciences bedrijf in een klinische fase, richt zich op onderzoek en ontwikkeling van anti-fibrotische en anti-inflammatoire therapieën voor de behandeling van hartziekten. De belangrijkste productkandidaat is CardiolRx, dat zich in een multinationale, gerandomiseerde, dubbelblinde en placebogecontroleerde Fase II-studie bevindt om de werkzaamheid en veiligheid van CardiolRx te evalueren bij acute myocarditis en voor de behandeling van terugkerende pericarditis. Het bedrijf ontwikkelt ook CRD-38 injectie voor subcutane toediening die zich in preklinische ontwikkeling bevindt voor de behandeling van hartfalen.

Cardiol Therapeutics Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Cardiol Therapeutics zich tot de beurswaarde?
CRDL fundamentele statistieken
Marktkapitalisatie	CA$180.29m
Inkomsten(TTM)	-CA$29.34m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-6.4x

Koers/Winstverhouding

Is CRDL overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
CRDL resultatenrekening (TTM)
Inkomsten	CA$0
Kosten van inkomsten	CA$0
Brutowinst	CA$0
Overige uitgaven	CA$29.34m
Inkomsten	-CA$29.34m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.42
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde CRDL op de lange termijn?

Bekijk historische prestaties en vergelijking

CRDL Overzicht aandelen

Beloningen

Risicoanalyse

Cardiol Therapeutics Inc. Concurrenten

TSXV:DMT

CA$50.4m

TSXV:NGEN

CA$170.5m

CNSX:PLTH

CA$263.4m

TSX:OGI

CA$254.1m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Cardiol Therapeutics Inc. Achieves Target Patient Enrollment in its Phase II Archer Trial Investigating CardiolRxTM for Acute Myocarditis

We're Not Very Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate

Cardiol Therapeutics Announces Completion of the Maveric Phase II Study in Recurrent Pericarditis with Results to Be Presented At the American Heart Association Scientific Sessions 2024

President recently bought CA$138k worth of stock

Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Deliver On Growth Plans?

Cardiol Therapeutics Inc., Annual General Meeting, Jul 26, 2024

Recent updates

Cardiol Therapeutics Inc. Achieves Target Patient Enrollment in its Phase II Archer Trial Investigating CardiolRxTM for Acute Myocarditis

We're Not Very Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate

Cardiol Therapeutics Announces Completion of the Maveric Phase II Study in Recurrent Pericarditis with Results to Be Presented At the American Heart Association Scientific Sessions 2024

President recently bought CA$138k worth of stock

Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Deliver On Growth Plans?

Cardiol Therapeutics Inc., Annual General Meeting, Jul 26, 2024

New major risk - Share price stability

New minor risk - Share price stability

Cardiol Therapeutics Inc. Announces It Has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis

Will Cardiol Therapeutics (TSE:CRDL) Spend Its Cash Wisely?

Cardiol Therapeutics Inc. Announces Massachusetts General Hospital as the 8th Major Medical Centre Participating in MAvERIC-Pilot

New minor risk - Shareholder dilution

Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Cardiol Therapeutics Inc. Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in Model of Heart Failure with Preserved Ejection Fraction

Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in Archer, A Phase II Trial of Cardiolrx™ for the Treatment of Acute Myocarditis

Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Invest In Growth?

We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

Consensus EPS estimates upgraded to CA$0.37 loss

Cardiol Therapeutics Inc., Annual General Meeting, Jun 28, 2023

We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth

Cardiol Therapeutics Inc. Announces First Patient Enrolled in Phase II Study Evaluating Cardiolrx for the Treatment of Recurrent Pericarditis

Cardiol Therapeutics Inc. Announces the Initiation of a Phase II Open-Label Pilot Study (NCT05494788), to Investigate the Tolerance, Safety, and Efficacy of CardiolRx in Patients with Recurrent Pericarditis

No longer forecast to breakeven

Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

High number of new and inexperienced directors

Price target increased to CA$4.50

Cardiol Therapeutics Inc. Announces Study Results Demonstrating Protective Effects of Cardiolrx in A Model of Acute Pericarditis

Cardiol Therapeutics Prioritizes Phase II Clinical Programs in Underserved Heart Diseases

Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating Cardiolrx Inhibits

We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth

Consensus forecasts updated

Cardiol Therapeutics Inc. Announces First Patient Enrolled in Archer, A Phase II Clinical Trial of Cardiolrx(TM) for Treatment of Acute Myocarditis

Consensus forecasts updated

Consensus forecasts updated

Cardiol Therapeutics Inc. Announces Board Appointments

Cardiol Therapeutics Announces FDA Investigational New Drug Application Authorization for Multicenter Phase II Open-Label Pilot Study of Cardiolrx for Recurrent Pericarditis

Price target decreased to CA$7.50

High number of new and inexperienced directors

Cardiol Therapeutics Inc., Annual General Meeting, Jun 28, 2022

We're Not Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn

Independent Chairman recently bought CA$121k worth of stock

Price target decreased to CA$10.83

Cardiol Therapeutics Inc. Receives Clearance from the FDA and Regulatory Agencies in Brazil and Mexico for Important Protocol Amendments in Lancer Trial

High number of new and inexperienced directors

No longer forecast to breakeven

Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Independent Director exercised options to buy CA$97k worth of stock.

Cardiol Therapeutics Receives FDA Clearance of Investigational New Drug (Ind) Application for Phase II Clinical Trial of CardiolRx(TM) for Acute Myocarditis

We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

Cardiol Therapeutics Common Shares Class A Deleted from Other OTC

High number of new directors

Price target increased to CA$9.57

Cardiol Therapeutics Inc. has completed a Composite Units Offering in the amount of CAD 22.0032 million.

Cardiol Therapeutics Announces First Patient Enrolled in Lancer, A Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with Covid-19

Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Consensus forecasts updated

Independent Director exercised options to buy CA$88k worth of stock.

Independent Director recently bought CA$99k worth of stock

New 90-day high: CA$3.72